155 results on '"Squassante, Lisa"'
Search Results
2. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome
3. Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man
4. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)
5. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder
6. Additional file 11 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
7. Additional file 7 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
8. Additional file 2 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
9. Additional file 5 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
10. Additional file 4 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
11. Additional file 9 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
12. Additional file 3 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
13. Additional file 8 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
14. Additional file 6 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome
15. Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers
16. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study
17. Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h
18. 6.9 CLUSTERS OF MENTAL HEALTH COMORBIDITIES AND CONCOMITANT MEDICATIONS OF PARTICIPANTS IN THREE RANDOMIZED CONTROLLED TRIALS (VANILLA, V1ADUCT, AV1ATION) WITH AUTISM SPECTRUM DISORDER
19. A PHASE 2 RANDOMIZED CONTROLLED TRIAL OF BALOVAPTAN IN PEDIATRIC PARTICIPANTS WITH AUTISM SPECTRUM DISORDER
20. Dose Linearity of Lacidipine Pharmacokinetics After Single and Repeated Oral Doses in Healthy Volunteers
21. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal
22. Population Pharmacokinetic-Pharmacodynamic Model of Craving in an Enforced Smoking Cessation Population: Indirect Response and Probabilistic Modeling
23. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.
24. Ketamine displaces the novel NMDA receptor SPET probe [ 123I]CNS-1261 in humans in vivo
25. Preclinical and Clinical Pharmacology of Basmisanil, a Novel Selective GABAA-α5 Receptor Negative Allosteric Modulator
26. EEG power spectra and auditory P300 during free smoking and enforced smoking abstinence
27. Dose Linearity of Lacidipine Pharmacokinetics After Single and Repeated Oral Doses in Healthy Volunteers
28. Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving
29. Absolute Quantification of Cerebral Blood Flow With Magnetic Resonance, Reproducibility of the Method, and Comparison With H215O Positron Emission Tomography
30. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects
31. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
32. Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6-month longitudinal study
33. 5.13 Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (Vanilla)
34. 5.14 Psychometric Properties of a Novel Vineland-II 2-Domain Composite Score to Assess Social Communication and Social Interaction in ASD
35. Characterization of a 7% carbon dioxide (C[O.sub.2]) inhalation paradigm to evoke anxiety symptoms in healthy subjects
36. Health-Related Quality of Life in Individuals with Down Syndrome: Results from a Non-Interventional Longitudinal Multi-National Study
37. Erratum: A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder
38. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder
39. Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6‐month longitudinal study.
40. 5.14 Psychometric Properties of a Novel Vineland-II 2-Domain Composite Score to Assess Social Communication and Social Interaction in ASD
41. Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study
42. RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273)
43. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers
44. Efficacy of Vestipitant, A Neurokinin-1 Receptor Antagonist, in Primary Insomnia
45. Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study.
46. The Orexin Antagonist SB-649868 Promotes and Maintains Sleep in Men with Primary Insomnia
47. Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational Insomnia
48. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder
49. Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
50. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.